Cargando…
GLUT1 and TUBB4 in Glioblastoma Could be Efficacious Targets
Glioblastoma multiforme (GBM) is the most aggressive and deadly brain tumor, portending a median 13-month survival even following gross total resection with adjuvant chemotherapy and radiotherapy. This prognosis necessitates improved therapies for the disease. A target of interest for novel chemothe...
Autores principales: | Guda, Maheedhara R., Labak, Collin M., Omar, Sara Ibrahim, Asuthkar, Swapna, Airala, Subra, Tuszynski, Jack, Tsung, Andrew J., Velpula, Kiran K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771132/ https://www.ncbi.nlm.nih.gov/pubmed/31491891 http://dx.doi.org/10.3390/cancers11091308 |
Ejemplares similares
-
Targeting RGS4 Ablates Glioblastoma Proliferation
por: Guda, Maheedhara R., et al.
Publicado: (2020) -
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017) -
Methylation regulates HEY1 expression in glioblastoma
por: Tsung, Andrew J., et al.
Publicado: (2017) -
Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism
por: Guda, Maheedhara R., et al.
Publicado: (2022) -
Immunopathology of galectin-3: an increasingly promising target in COVID-19
por: Caniglia, John L., et al.
Publicado: (2020)